IMPORTANCE: Nonmelanoma skin cancer (NMSC) is the most common cancer and predominantly affects older patients. Because NMSCs do not typically affect survival or short-term quality of life, the decision about whether and how to treat patients with limited life expectancy (LLE) is challenging, especially for asymptomatic tumors. OBJECTIVE: To compare treatment patterns and clinical outcomes of patients with NMSC with and without LLE. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study of 1536 consecutive patients diagnosed with NMSC at 2 dermatology clinics: a university-based private practice and a Veterans Affairs Medical Center in San Francisco, California. Patients were recruited in 1999 through 2000 and followed up for a median of 9 years. A total of 1360 patients with 1739 tumors (90%) were included in the final analysis. Limited life expectancy was defined as patients either 85 years or older at the time of diagnosis or patients with multiple comorbidities (Charlson Comorbidity Index of ≥ 3). Treatment options included no treatment, destruction, or 2 types of surgery-elliptical excision or Mohs surgery. MAIN OUTCOMES AND MEASURES: Treatment type. RESULTS: Most NMSCs (69%) were treated surgically, regardless of patient life expectancy. The choice of surgery was not influenced by patient prognosis in univariate or multivariable models adjusted for tumor and patient characteristics. Many patients with LLE (43%) died within 5 years, none of NMSC. Tumor recurrence was rare (3.7% at 5 years [95% CI, 2.6%-4.7%]) in all patients. Although serious complications were unusual, approximately 20% of patients with LLE reported complications of therapy, compared with 15% of other patients. CONCLUSIONS AND RELEVANCE: Most NMSCs are treated surgically, regardless of the patient's life expectancy. Given the very low tumor recurrence rates and high mortality from causes unrelated to NMSC in patients with LLE, clinicians should consider whether these patients would prefer less invasive treatment strategies.
IMPORTANCE: Nonmelanoma skin cancer (NMSC) is the most common cancer and predominantly affects older patients. Because NMSCs do not typically affect survival or short-term quality of life, the decision about whether and how to treat patients with limited life expectancy (LLE) is challenging, especially for asymptomatic tumors. OBJECTIVE: To compare treatment patterns and clinical outcomes of patients with NMSC with and without LLE. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study of 1536 consecutive patients diagnosed with NMSC at 2 dermatology clinics: a university-based private practice and a Veterans Affairs Medical Center in San Francisco, California. Patients were recruited in 1999 through 2000 and followed up for a median of 9 years. A total of 1360 patients with 1739 tumors (90%) were included in the final analysis. Limited life expectancy was defined as patients either 85 years or older at the time of diagnosis or patients with multiple comorbidities (Charlson Comorbidity Index of ≥ 3). Treatment options included no treatment, destruction, or 2 types of surgery-elliptical excision or Mohs surgery. MAIN OUTCOMES AND MEASURES: Treatment type. RESULTS: Most NMSCs (69%) were treated surgically, regardless of patient life expectancy. The choice of surgery was not influenced by patient prognosis in univariate or multivariable models adjusted for tumor and patient characteristics. Many patients with LLE (43%) died within 5 years, none of NMSC. Tumor recurrence was rare (3.7% at 5 years [95% CI, 2.6%-4.7%]) in all patients. Although serious complications were unusual, approximately 20% of patients with LLE reported complications of therapy, compared with 15% of other patients. CONCLUSIONS AND RELEVANCE: Most NMSCs are treated surgically, regardless of the patient's life expectancy. Given the very low tumor recurrence rates and high mortality from causes unrelated to NMSC in patients with LLE, clinicians should consider whether these patients would prefer less invasive treatment strategies.
Authors: Alvin C Kwok; Marcus E Semel; Stuart R Lipsitz; Angela M Bader; Amber E Barnato; Atul A Gawande; Ashish K Jha Journal: Lancet Date: 2011-10-05 Impact factor: 79.321
Authors: Mary-Margaret Chren; Jeanette S Torres; Sarah E Stuart; Daniel Bertenthal; Remedios J Labrador; W John Boscardin Journal: Arch Dermatol Date: 2011-05
Authors: Mary-Margaret Chren; Anju P Sahay; Laura P Sands; Leah Maddock; Karla Lindquist; Daniel Bertenthal; Peter Bacchetti Journal: Med Care Date: 2004-10 Impact factor: 2.983
Authors: Tamara Salam Housman; Steven R Feldman; Phillip M Williford; Alan B Fleischer; Neal D Goldman; Jose M Acostamadiedo; G John Chen Journal: J Am Acad Dermatol Date: 2003-03 Impact factor: 11.527
Authors: Niki B Vora; Karen L Connolly; Stephen Dusza; Anthony M Rossi; Kishwer S Nehal; Erica H Lee Journal: J Am Acad Dermatol Date: 2020-04-19 Impact factor: 11.527
Authors: Mark S Nestor; Brian Berman; David Goldberg; Armand B Cognetta; Michael Gold; William Roth; Clay J Cockerell; Brad Glick Journal: J Clin Aesthet Dermatol Date: 2019-02-01
Authors: Laura J Esserman; Ian M Thompson; Brian Reid; Peter Nelson; David F Ransohoff; H Gilbert Welch; Shelley Hwang; Donald A Berry; Kenneth W Kinzler; William C Black; Mina Bissell; Howard Parnes; Sudhir Srivastava Journal: Lancet Oncol Date: 2014-05 Impact factor: 41.316
Authors: M R Wehner; N Dalma; C Landefeld; A Pare-Anastasiadou; I Koutelidas; M M Chren; N Aji; C E Teng; B A Koenig; J Tang; K Covinsky; E Linos Journal: Br J Dermatol Date: 2018-07-12 Impact factor: 9.302
Authors: Emma M Rogers; Karen L Connolly; Kishwer S Nehal; Stephen W Dusza; Anthony M Rossi; Erica Lee Journal: J Am Acad Dermatol Date: 2017-12-27 Impact factor: 11.527